Cue Biopharma, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Cue Biopharma, Inc. (CUE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -4.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-16
- Cue Biopharma, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -4.30%.
- Cue Biopharma, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -3.80%, a 290.00% decline from fiscal 2023.
- Cue Biopharma, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 2.00%, a 100.00% increase from fiscal 2022.
- Cue Biopharma, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was 1.00%, a 0.00% change from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -4.30% 10-K · filed 2026-03-16 | |
| 2024-12-31 | -3.80% 10-K · filed 2026-03-16 | 4.00% 10-K · filed 2025-03-31 |
| 2023-12-31 | 2.00% 10-K · filed 2025-03-31 | |
| 2022-12-31 | 1.00% 10-K · filed 2024-03-28 | |
| 2021-12-31 | 1.00% 10-K · filed 2023-03-21 | |
| 2020-12-31 | -2.00% 10-K · filed 2022-03-16 | |
| 2019-12-31 | 1.00% 10-K · filed 2021-03-09 | |
| 2018-12-31 | 3.00% 10-K · filed 2020-03-12 | |
| 2017-12-31 | 2.00% 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |